To date, only 2 case reports have documented instances of patients with ICCs harboring MET fusions (specifically EHBP1‐MET or CAPZA-2-MET) that were sensitive to MET inhibitors crizotinib or capmatinib, respectively.6,16 In this case report, we describe a patient with ICC harboring a novel RBPMS-MET fusion who experienced a remarkable response to crizotinib. Here, RBPMS is linked to intrahepatic cholangiocarcinoma.